What is OLMA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.68B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for OLMA?

P/E (TTM) is n/a and 52-week range is $6.65 to $36.26 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s OLMA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for OLMA?

The company profile lists net income (TTM) near $-185M, EPS (TTM) near $-2.12 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Olema Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Francisco, California, US, 87.3M shares outstanding, ISIN US68062P1066 when available from company profile and filing metadata.

Olema Pharmaceuticals Inc

$OLMA

Health Care · Biotechnology

IR Run Scenarios

$7.82

+0.00%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. The company is headquartered in San Francisco, California and currently employs 131 full-time employees. The company went IPO on 2020-11-19. The firm is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. The company is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. The company is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.

Employees

131

Website

olema.com/

IPO

2020-11-19

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)